This is a StreetInsider.com Premium Only Page

(LYRA) – Press Releases

Mar 21, 2024 04:01 PM Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023 04:01 PM Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023 07:00 AM Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023 07:00 AM Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

Sep 12, 2023 07:00 AM Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Sep 6, 2023 08:00 AM Lyra Therapeutics to Participate in Upcoming Investor Conferences

Aug 29, 2023 07:00 AM Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023 04:01 PM Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023 07:30 AM Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 2, 2023 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023 07:30 AM Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023 07:29 AM Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023 07:57 AM Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023 07:00 AM Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023 04:01 PM Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023 07:59 AM Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Mar 29, 2023 04:06 PM Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023 07:59 AM Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023 07:56 AM Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Jan 17, 2023 06:42 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 9, 2022 08:00 AM Lyra Therapeutics to Present at Upcoming Investor Conferences

Nov 8, 2022 04:01 PM Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 13, 2022 07:00 AM Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022 08:00 AM LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022 07:00 AM Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022 07:00 AM Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022 07:00 AM Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022 07:00 AM Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022 07:00 AM Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

Jul 5, 2022 07:00 AM Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jun 17, 2022 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 26, 2022 07:00 AM Lyra Therapeutics to Present at Upcoming Investor Conferences

May 10, 2022 07:00 AM Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 5, 2022 07:00 AM Lyra Therapeutics to Present at Upcoming Investor Conferences

Apr 29, 2022 09:07 AM Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Apr 25, 2022 07:00 AM Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Apr 21, 2022 07:00 AM Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

Apr 13, 2022 07:00 AM Lyra Therapeutics Announces Closing of $100.5 Million Private Placement

Apr 8, 2022 07:34 AM Lyra Therapeutics Announces $100.5 Million Private Placement

Mar 9, 2022 07:00 AM Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 7, 2022 07:00 AM Lyra Therapeutics Appoints Jim Tobin to Board of Directors

Feb 28, 2022 07:00 AM Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Feb 17, 2022 07:00 AM Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman

Jan 24, 2022 07:00 AM Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Nov 11, 2021 07:00 AM Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

Nov 9, 2021 04:05 PM Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 2, 2021 07:00 AM Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9

Oct 19, 2021 07:00 AM Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts